Welcome to our dedicated page for Alzamend Neuro SEC filings (Ticker: ALZN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Alzamend Neuro, Inc. (ALZN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Alzamend Neuro is a clinical-stage biopharmaceutical company whose common stock is registered under Section 12(b) of the Exchange Act and trades on The Nasdaq Capital Market under the symbol ALZN, as noted in multiple Form 8-K filings.
Through this page, readers can review Alzamend Neuro’s current reports on Form 8-K, which cover a range of material events. Recent 8-K filings have disclosed unregistered sales of equity securities upon conversion of Series B convertible preferred stock into common stock, Certificates of Elimination for Series A, Series B and Series C convertible preferred stock, audited financial results furnished via press release, and corporate developments such as the passing of a director. These filings also confirm the company’s status as an emerging growth company and list its Nasdaq trading information.
In addition to 8-Ks, investors may consult Alzamend Neuro’s annual report on Form 10-K and other periodic reports, which are referenced in the company’s press releases. These documents typically include details on its clinical-stage pipeline (AL001 and ALZN002), licensing arrangements with the University of South Florida Research Foundation, Inc., risk factors and financial condition.
On Stock Titan, SEC documents are paired with AI-powered summaries that explain the key points of each filing in plain language. Users can quickly see what a particular 8-K, 10-K or other report means for Alzamend Neuro’s capital structure, clinical programs or governance without reading every page. Filings are updated as they appear on EDGAR, and insider or equity-related disclosures, such as unregistered sales of securities, can be reviewed in context with the company’s broader regulatory history.
Alzamend Neuro filed Certificates of Elimination with the Delaware Secretary of State for its Series B and Series C convertible preferred stock. The filings, effective upon submission on October 14, 2025, remove from the company’s amended Certificate of Incorporation the matters set forth in the Certificates of Designations for these preferred series.
Copies of the Certificates of Elimination are included as Exhibits 3.1 (Series B) and 3.2 (Series C).
Milton C. Ault III, a director of Alzamend Neuro, Inc. (ALZN), reported a series of transactions in early October 2025. On 10/08/2025 he converted Series B convertible preferred shares into 61,743 shares of common stock at a conversion price of $2.32, increasing the indirect holdings reported for Ault Lending, LLC to 130,591 shares. That same day he sold 101,394 shares in open-market transactions at a volume-weighted average price of $2.4376 (trade range $2.42–$2.4634).
On 10/09/2025 he sold an additional 20,397 shares at $2.3234, leaving Ault Lending, LLC with 8,260 indirectly held shares. The filing also shows other indirect holdings: 11,068 shares via Ault Life Sciences, Inc. and 61 shares via Ault Life Sciences Fund, LLC, plus several warrants totaling 23,334 underlying common shares across three warrant issuances.
Alzamend Neuro, Inc. reported that between October 1 and October 8, 2025 it issued 361,743 shares of common stock upon conversion of approximately 839.2 shares of its Series B Convertible Preferred Stock. These issuances were made in reliance on a private offering exemption under Section 4(a)(2) of the Securities Act, meaning the new common shares were not registered with the SEC at the time of issuance.
Following these conversions, Alzamend Neuro had 3,801,604 shares of common stock outstanding as of October 8, 2025. The filing also notes standard Inline XBRL exhibit information related to the cover page data.
Milton C. Ault III, a director of Alzamend Neuro, Inc. (ALZN), reported multiple insider transactions in October 2025. He converted Series B preferred shares into 100,000 common shares on 10/03/2025 and again on 10/07/2025, and sold portions of common stock in open-market transactions: 82,033 shares on 10/06/2025 at a VWAP of $2.4535 and 57,379 shares on 10/07/2025 at a VWAP of $2.4914. After these moves, beneficial ownership is reported indirectly through entities including Ault Lending, LLC, Ault Life Sciences, Inc., and Ault Life Sciences Fund, LLC. The filings disclose outstanding warrants and converted preferred stock that underlie additional common shares.
Alzamend Neuro, Inc. holders led by Milton C. Ault III report combined beneficial ownership of 166,909 shares, representing approximately 4.4% of the company's 3,739,861 outstanding shares as of October 7, 2025. The filing aggregates direct holdings, shares underlying Series B convertible preferred stock and exercisable warrants, and stock options across related entities including Hyperscale Data, Ault Lending, Ault Life Sciences and others.
The statement breaks out voting and dispositive power: Mr. Ault holds 1,843 shares directly and shared voting power over 165,066 shares; Hyperscale Data and Ault Lending each report beneficial ownership of roughly 153,937 and 153,925 shares respectively (about 4.0%). Purchase prices for several block holdings are disclosed in aggregate dollar amounts, and no transactions in the past 60 days are reported except as listed in an exhibit.
Alzamend Neuro (ALZN) filed Amendment No. 10 to Schedule 13D, updating beneficial ownership by Milton C. Ault III and affiliated entities. The filing is based on 3,539,861 shares outstanding as of October 2, 2025.
Mr. Ault may be deemed to beneficially own 306,321 shares, or approximately 8.0% of the class, including direct holdings and shares attributable through affiliates. Hyperscale Data, Inc. reports 293,349 shares (approximately 7.7%), and Ault Lending, LLC reports 293,337 shares (approximately 7.7%). These positions include 261,743 shares underlying Series B Convertible Preferred Stock and 23,334 shares underlying currently exercisable warrants held by Ault Lending, plus smaller direct common holdings across affiliates.
The filing details voting and dispositive powers across entities and notes that no transactions in the past 60 days occurred other than those listed in an exhibit.
Milton C. Ault III, a director of Alzamend Neuro, Inc. (ALZN), reported multiple transactions in early October 2025. On 10/01/2025 he converted Series B convertible preferred shares into 100,000 shares of common stock at a conversion price of $2.32. On 10/01–10/03/2025 he sold common shares in open-market transactions: 36,777 shares on 10/01 at a VWAP of $2.3487, 20,686 shares on 10/02 at $2.394, and 65,903 shares on 10/03 at a VWAP of $2.4413, totaling 123,366 shares sold.
The Form 4 lists changing beneficial ownership figures tied to Ault-controlled entities: following the conversion Ault Lending is reported with 131,626 shares beneficially owned, which moved to 94,849, then 74,163, and then 8,260 after the sales. Additional holdings are shown for Ault Life Sciences, Inc. (11,068) and Ault Life Sciences Fund, LLC (61), with voting and investment power described in the filing.
Alzamend Neuro, Inc. (ALZN) Schedule 13D/A discloses that Milton C. Ault, III and affiliated entities beneficially own a combined 429,687 common shares, representing approximately 11.2% of the 3,439,861 shares outstanding reported by the issuer. That total includes direct holdings, stock options, warrants and shares underlying Series B convertible preferred stock held across Hyperscale Data, Ault Lending, Ault Life Sciences and related entities.
The filing breaks out ownership and voting/dispositive power: Mr. Ault directly holds 1,843 shares and shares control of 427,844 shares; Hyperscale Data and Ault Lending each report approximately 10.9% beneficial ownership. The filing states sources of funds for purchases (working capital or personal funds) and lists aggregate purchase prices for several holdings and instruments. No transactions in the past 60 days are reported except as set forth in Exhibit 1.
Milton C. Ault III, identified as a director and a 10% owner of Alzamend Neuro, Inc. (ALZN), reported multiple sales of the company’s common stock in late September 2025. The filings show sales on 09/26/2025 of 37,738 shares at $2.3145, on 09/29/2025 of 38,324 shares at $2.309, and on 09/30/2025 of 3,566 shares at $2.3334. After those transactions, beneficial ownership reported for the related entities was 73,516 shares (indirect) by Ault Lending, LLC, 35,192 shares (indirect) by Ault Lending, LLC, and 31,626 shares (indirect) by Ault Lending, LLC, respectively. Additional holdings include 11,068 shares held indirectly by Ault Life Sciences, Inc. and 61 shares indirectly by Ault Life Sciences Fund, LLC. The Form 4 is signed by Mr. Ault on 09/30/2025.
Alzamend Neuro, Inc. (ALZN) Schedule 13D/A discloses that Milton C. Ault, III and affiliated entities collectively beneficially own 509,315 shares, equal to approximately 13.3% of the 3,439,861 shares outstanding reported to the reporting persons. Related entities Hyperscale Data, Inc. and Ault Lending, LLC are reported to beneficially own approximately 496,343 shares (13.0%) and 496,331 shares (13.0%), respectively.
The filing states sources of funds (working capital, personal funds) and itemizes aggregate purchase prices for specific holdings and convertible instruments (for example, ~839.24 shares of Series B convertible preferred and related warrants for approximately $839,245). Item 5 notes no transactions in the past 60 days except as set forth in Exhibit 1.